Biogen taps Dorsa to succeed Papadopoulos as chair

With longtime chair Stelios Papadopoulos’ mandatory retirement imminent, Biogen Inc. (NASDAQ:BIIB) has elected Caroline Dorsa to succeed him, effective after the company’s June 14 annual meeting. Dorsa, a Biogen director since 2010, was EVP and CFO of Public Service Enterprise Group Inc in 2009-15. The board change follows closely the arrival of President and CEO Chris Viehbacher in November; he has taken leadership of Biogen as it prepares to launch two important drugs, and looks to external sources of innovation while reshaping its current business.

AMR Action Fund-backed Venatorx Pharmaceuticals Inc. appointed Tomas Heyman as chair. Heyman spent 27 years at Johnson & Johnson (NYSE:JNJ) and its affiliates in the U.S. and Belgium, retiring in September 2019. The company also announced that Michael Diem has stepped down from its board as independent director after six years. Venatorx is developing treatments for drug resistant microbial infections...